

DAFTAR PUSTAKA

1. Alena Klochko MD. Salmonella Infection (Salmonellosis) [Internet]. Vol. 2018. 2017. Available from: <https://emedicine.medscape.com/article/228174-overview>
2. Nester EW, Jr DA, Roberts CE. Microbiology: a Human Perspective. 7th ed. Mc-Graw Hill, New York, NY, USA; 2012.
3. Setiabudy R. Antimikroba Lain. In: Farmakologi dan Terapi. 5th ed. Jakarta, Indonesia: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia; 2007. p. 584–96.
4. Guo C, Rosoha E, Lowry MB, Borregaard N, Gombart AF. Curcumin induces human cathelicidin antimicrobial peptide gene expression through a vitamin D receptor-independent pathway. *J Nutr Biochem.* 2012/07/31 ed. 2013;24(5):754–9.
5. Tajbakhsh S, Mohammadi K, Deilami I, Zandi K, Fouladvand M, Ramedani E, et al. Antibacterial activity of indium curcumin and indium diacetylcurcumin. Vol. 7. 2008. 3832-3835 p.
6. Robertson RPL, Wahab MFA, Raasch FOC, Avery J, Anderson R, Owens C, et al. Evaluation of Chloramphenicol and Ampicillin in Salmonella Enteric Fever. *N Engl J Med* [Internet]. 1968;278(4):171–6. Available from: <http://www.nejm.org/doi/full/10.1056/NEJM196801252780401>
7. Butler T, Rumans L, Arnold K. Response of typhoid fever caused by chloramphenicol-susceptible and chloramphenicol-resistant strains of *Salmonella typhi* to treatment with trimethoprim-sulfamethoxazole. *Rev Infect Dis.* 1982/03/01 ed. 1982;4(2):551–61.
8. Lampe RM, Duangmani C, Mansuwan P. Chloramphenicol- and ampicillin-resistant typhoid fever. *JAMA* [Internet]. 1975;233(7):768. Available from: <http://dx.doi.org/10.1001/jama.1975.03260070018007>
9. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid fever. *Clin Infect Dis* [Internet]. 2010;50(2):241–6. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798017/>
10. Kariuki S, Revathi G, Kiiru J, Mengo DM, Mwituria J, Muyodi J, et al. Typhoid in Kenya is associated with a dominant multidrug-resistant *Salmonella enterica* serovar Typhi haplotype that is also widespread in Southeast Asia. *J Clin Microbiol.* 2010/04/16 ed. 2010;48(6):2171–6.

11. Dolecek C, Tran TP, Nguyen NR, Le TP, Ha V, Phung QT, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. *PLoS One*. 2008/05/22 ed. 2008;3(5):e2188.
12. Kumar Y, Sharma A, Mani K. High Level of Resistance to nalidixic acid in *Salmonella enterica* serovar Typhi in Central India. Vol. 3. 2009. 467-469 p.
13. Dong B-Q, Yang J, Wang X-Y, Gong J, von Seidlein L, Wang M-L, et al. Trends and disease burden of enteric fever in Guangxi province, China, 1994–2004. *Bull World Health Organ* [Internet]. 2010;88(9):689–96. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2930361/>
14. Nizet V, Gallo RL. Cathelicidins and innate defense against invasive bacterial infection. *Scand J Infect Dis*. 2003/11/19 ed. 2003;35(9):670–6.
15. Brat P, Tourniaire F, Amiot-Carlin M-J. Stability and Analysis of Phenolic Pigments. 2007. 71-86 p.
16. Achmad SA, Hakim EH, Makmur L, Syah YM, Juliawaty LD, Mujahiddin D. Ilmu kimia dan kegunaan tumbuh-tumbuhan obat Indonesia. Intitute Teknol Bandung, Indones. 2007;
17. Rustam E, Atmasari L, Yanwirasti. Efek Antiinflamasi Ekstrak Etanol Kunyit (*Curcuma domestica* Val) Pada Tikus Jantan Galur Wistar. *J Sains dan Teknol Farm*. 2007;12:112–5.
18. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of *Curcuma longa*: a review of preclinical and clinical research. *Altern Med Rev*. 2009/07/15 ed. 2009;14(2):141–53.
19. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (*Curcuma longa*). *J Altern Complement Med*. 2003/04/05 ed. 2003;9(1):161–8.
20. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. *J Neuropathol Exp Neurol*. 2004/09/30 ed. 2004;63(9):901–10.
21. Ravindran J, Subbaraju G V, Ramani M V, Sung B, Aggarwal BB. Bisdemethylcurcumin and structurally related hispolon analogues of curcumin exhibit enhanced prooxidant, anti-proliferative and anti-inflammatory activities in vitro. *Biochem Pharmacol*. 2010/02/09 ed. 2010;79(11):1658–66.
22. Jacob A, Wu R, Zhou M, Wang P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. *PPAR Res*. 2008/02/16 ed.

- 2007;2007:89369.
23. Majeed M, Badmaev V, R n D Team S. Curcuminoids - antioxidant phytonutrients. 2003.
 24. Venkatesan P, Unnikrishnan MK, Sudheer Kumar M, Rao M. Effect of curcumin analogues on oxidation of haemoglobin and lysis of erythrocytes. Vol. 84. 2003. 74-78 p.
 25. Huang MT, Wang ZY, Georgiadis CA, Laskin JD, Conney AH. Inhibitory effects of curcumin on tumor initiation by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene. *Carcinogenesis*. 1992/11/01 ed. 1992;13(11):2183–6.
 26. Ramprasad C, Sirsi M. Studies on Indian medicinal plants: *Curcuma longa* Linn. - Effect of curcumin and the essential oils of *Curcuma longa* on bile secretion. Vol. 15. 1956. 262-265 p.
 27. SHIH ANL, HARRIS ND. Antimicrobial Activity of Selected Antioxidants. *J Food Prot* [Internet]. 1977;40(8):520–2. Available from: <http://jfoodprotection.org/doi/abs/10.4315/0362-028X-40.8.520>
 28. Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay K. Bactericidal Activity of Curcumin Is Associated with Damaging of Bacterial Membrane. *PLoS One* [Internet]. 2015;10(3):e0121313. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374920/>
 29. Rai D, Singh JK, Roy N, Panda D. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. *Biochem J*. 2007/10/24 ed. 2008;410(1):147–55.
 30. Wang J, Zhou X, Li W, Deng X, Deng Y, Niu X. Curcumin protects mice from *Staphylococcus aureus* pneumonia by interfering with the self-assembly process of alpha-hemolysin. *Sci Rep*. 2016/06/28 ed. 2016;6:28254.
 31. Siwipeni Irmawanti Rahayu, Nurdiana Nurdiana, Santoso S. The Effect of Curcumin and Cotrimoxazole in *Salmonella Typhimurium* Infection In Vivo. *ISRN Microbiol*. 2013;2013:4.
 32. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? *Nat Rev Microbiol*. 2005/02/11 ed. 2005;3(3):238–50.
 33. Giuliani A, Pirri G, Nicoletto SF. Antimicrobial peptides: an overview of a promising class of therapeutics. *Cent Eur J Biol* [Internet]. 2007;2(1):1–33. Available from: <https://doi.org/10.2478/s11535-007-0010-5>

34. Steinmann J. Induction and regulation of CAMP gene expression. Department of Biology. [Reykjavík, Iceland]: University of Iceland; 2008.
35. Ganz T. Defensins: antimicrobial peptides of innate immunity. *Nat Rev Immunol.* 2003/09/02 ed. 2003;3(9):710–20.
36. Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human beta-defensins. *Cell Mol Life Sci.* 2006/05/20 ed. 2006;63(11):1294–313.
37. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. *Biochim Biophys Acta.* 2006/05/24 ed. 2006;1758(9):1408–25.
38. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. *J Leukoc Biol.* 2003/09/10 ed. 2004;75(1):39–48.
39. Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. *J Invest Dermatol.* 2003/04/26 ed. 2003;120(5):810–6.
40. Zanetti M, Gennaro R. Cathelicidins : a novel protein family with a common proregion and a variable C-terminal antimicrobial domain Margherita Zanetti a¹, b²*, Renato Gennaro b², D o m e n i c o. 1995;374:1–5.
41. Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. *Microbes Infect.* 2002/03/23 ed. 2002;4(3):361–72.
42. Pestonjamas VK, Huttner KH, Gallo RL. Processing site and gene structure for the murine antimicrobial peptide CRAMP. *Peptides.* 2001/10/06 ed. 2001;22(10):1643–50.
43. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. *Eur J Biochem.* 1996/06/01 ed. 1996;238(2):325–32.
44. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. *Infect Immun* [Internet]. 1995;63(4):1291–7. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC173149/>
45. Zaiou M, Gallo RL. Cathelicidins, essential gene-encoded mammalian antibiotics. *J Mol Med.* 2002/09/13 ed. 2002;80(9):549–61.
46. Tomasinsig L, Zanetti M. The cathelicidins--structure, function and evolution.

- Curr Protein Pept Sci. 2005/01/11 ed. 2005;6(1):23–34.
47. Gennaro R, Zanetti M. Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. *Biopolymers*. 2000/08/10 ed. 2000;55(1):31–49.
 48. Johansson J, Gudmundsson GH, Rottenberg ME, Berndt KD, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. *J Biol Chem*. 1998/03/07 ed. 1998;273(6):3718–24.
 49. Oren Z, Lerman JC, Gudmundsson GH, Agerberth B, Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. *Biochem J* [Internet]. 1999;341(Pt 3):501–13. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1220385/>
 50. Porcelli F, Verardi R, Shi L, Henzler-Wildman KA, Ramamoorthy A, Veglia G. NMR structure of the cathelicidin-derived human antimicrobial peptide LL-37 in dodecylphosphocholine micelles. *Biochemistry*. 2008/04/29 ed. 2008;47(20):5565–72.
 51. Scott MG, Davidson DJ, Gold MR, Bowdish D, Hancock RE. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. *J Immunol*. 2002/09/24 ed. 2002;169(7):3883–91.
 52. Jeng L, Yamshchikov A V, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. *J Transl Med*. 2009/04/25 ed. 2009;7:28.
 53. Sorensen OE, Follin P, Johnsen AH, Calafat J, Tjabringa GS, Hiemstra PS, et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. *Blood*. 2001/06/05 ed. 2001;97(12):3951–9.
 54. Gombart AF, Borregaard N, Koeffler HP. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D₃. *FASEB J*. 2005/06/30 ed. 2005;19(9):1067–77.
 55. Hase K, Murakami M, Iimura M, Cole SP, Horibe Y, Ohtake T, et al. Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against *Helicobacter pylori*. *Gastroenterology*. 2004/01/16 ed. 2003;125(6):1613–25.

56. Wu H, Zhang G, Minton JE, Ross CR, Blecha F. Regulation of cathelicidin gene expression: induction by lipopolysaccharide, interleukin-6, retinoic acid, and *Salmonella enterica* serovar typhimurium infection. *Infect Immun.* 2000/09/19 ed. 2000;68(10):5552–8.
57. Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B, et al. Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulator. *Nat Med.* 2001/02/15 ed. 2001;7(2):180–5.
58. Bergman P, Johansson L, Asp V, Plant L, Gudmundsson GH, Jonsson AB, et al. *Neisseria gonorrhoeae* downregulates expression of the human antimicrobial peptide LL-37. *Cell Microbiol.* 2005/06/15 ed. 2005;7(7):1009–17.
59. Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol.* 2004/08/24 ed. 2004;173(5):2909–12.
60. Hase K, Eckmann L, Leopard JD, Varki N, Kagnoff MF. Cell differentiation is a key determinant of cathelicidin LL-37/human cationic antimicrobial protein 18 expression by human colon epithelium. *Infect Immun.* 2002/01/18 ed. 2002;70(2):953–63.
61. Schaubert J, Oda Y, Buchau AS, Yun QC, Steinmeyer A, Zugel U, et al. Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. *J Invest Dermatol.* 2007/10/19 ed. 2008;128(4):816–24.
62. Schaubert J, Svanholm C, Termen S, Iffland K, Menzel T, Scheppach W, et al. Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. *Gut.* 2003/04/15 ed. 2003;52(5):735–41.
63. Termen S, Tollin M, Rodriguez E, Sveinsdottir SH, Johannesson B, Cederlund A, et al. PU.1 and bacterial metabolites regulate the human gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells. *Mol Immunol.* 2008/07/29 ed. 2008;45(15):3947–55.
64. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, et al. Bactericidal activity of mammalian cathelicidin-derived peptides. *Infect Immun.* 2000/04/18 ed. 2000;68(5):2748–55.
65. De Y, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, et al. LL-37,

- the Neutrophil Granule–And Epithelial Cell–Derived Cathelicidin, Utilizes Formyl Peptide Receptor–Like 1 (Fpr1) as a Receptor to Chemoattract Human Peripheral Blood Neutrophils, Monocytes, and T Cells. *J Exp Med* [Internet]. 2000;192(7):1069–74. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2193321/>
66. Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H, et al. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. *Immunology*. 2002/04/26 ed. 2002;106(1):20–6.
 67. Koczulla R, von Degenfeld G, Kupatt C, Krotz F, Zahler S, Gloe T, et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. *J Clin Invest*. 2003/06/05 ed. 2003;111(11):1665–72.
 68. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sorensen O, Borregaard N, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. *J Invest Dermatol*. 2003/02/27 ed. 2003;120(3):379–89.
 69. Davidson DJ, Currie AJ, Reid GS, Bowdish DM, MacDonald KL, Ma RC, et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. *J Immunol*. 2004/01/07 ed. 2004;172(2):1146–56.
 70. Burton MF, Steel PG. The chemistry and biology of LL-37. *Nat Prod Rep*. 2009/11/26 ed. 2009;26(12):1572–84.
 71. Schmidtchen A, Frick IM, Andersson E, Tapper H, Bjorck L. Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. *Mol Microbiol*. 2002/10/09 ed. 2002;46(1):157–68.
 72. Deretic V, Kimura T, Timmins G, Moseley P, Chauhan S, Mandell M. Immunologic manifestations of autophagy. *J Clin Invest*. 2015/02/06 ed. 2015;125(1):75–84.
 73. Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. *Cell Host Microbe*. 2009/09/15 ed. 2009;6(3):231–43.
 74. Songane M, Kleinnijenhuis J, Netea MG, van Crevel R. The role of autophagy in host defence against *Mycobacterium tuberculosis* infection. *Tuberc*. 2012/06/12 ed. 2012;92(5):388–96.
 75. Duplantier AJ, van Hoek ML. The Human Cathelicidin Antimicrobial Peptide

- LL-37 as a Potential Treatment for Polymicrobial Infected Wounds. *Front Immunol.* 2013/07/11 ed. 2013;4:143.
76. Golec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. *Ann Agric Env Med.* 2007/07/28 ed. 2007;14(1):1–4.
77. Gombart AF, Bhan I, Borregaard N, Tamez H, Camargo Jr. CA, Koeffler HP, et al. Low plasma level of cathelicidin antimicrobial peptide (hCAP18) predicts increased infectious disease mortality in patients undergoing hemodialysis. *Clin Infect Dis.* 2009/01/13 ed. 2009;48(4):418–24.
78. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. Vitamin D, innate immunity and outcomes in community acquired pneumonia. *Respirology.* 2011/01/20 ed. 2011;16(4):611–6.
79. Urrutia-Pereira M, Sole D. [Vitamin D deficiency in pregnancy and its impact on the fetus, the newborn and in childhood]. *Rev Paul Pediatr.* 2015/02/11 ed. 2015;33(1):104–13.
80. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. *Gene.* 2004/08/19 ed. 2004;338(2):143–56.
81. Sidhu PS, Nassif N, McCallum MM, Teske K, Feleke B, Yuan NY, et al. Development of novel Vitamin D Receptor-Coactivator Inhibitors. *ACS Med Chem Lett.* 2014/05/07 ed. 2014;5(2):199–204.
82. Shin JS, Choi MY, Longtine MS, Nelson DM. Vitamin D Effects on Pregnancy and the Placenta. *Placenta [Internet].* 2010;31(12):1027–34. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2993775/>
83. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science (80-).* 2006/02/25 ed. 2006;311(5768):1770–3.
84. Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. *Cell Immunol.* 2012/12/19 ed. 2012;280(1):22–35.
85. Prietl B, Treiber G, Pieber TR, Amrein K. Vitamin D and immune function. *Nutrients.* 2013/07/17 ed. 2013;5(7):2502–21.
86. Pinheiro da Silva F, Machado MC. Antimicrobial peptides: clinical relevance and therapeutic implications. *Peptides.* 2012/06/05 ed. 2012;36(2):308–14.
87. Bartik L, Whitfield GK, Kaczmarek M, Lowmiller CL, Moffet EW, Furnick

- JK, et al. Curcumin: A Novel Nutritionally-Derived Ligand of the Vitamin D Receptor with Implications for Colon Cancer Chemoprevention. *J Nutr Biochem* [Internet]. 2010;21(12):1153–61. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891903/>
88. Dixon BM, Barker T, McKinnon T, Cuomo J, Frei B, Borregaard N, et al. Positive correlation between circulating cathelicidin antimicrobial peptide (hCAP18/LL-37) and 25-hydroxyvitamin D levels in healthy adults. *BMC Res Notes* [Internet]. 2012;5:575. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532295/>
 89. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. Jawetz, Melnick, & Adelberg's Medical Microbiology. Vol. 25th editi. McGraw-Hill Companies, Inc; 2010.
 90. Widoyono. Penyakit Tropis : Epidemiologi, Penularan, Pencegahan, dan Pemberantasannya. Jakarta, Indonesia: Erlangga; 2011.
 91. MacKenzie K, Palmer M, Köster W, White A. Examining the Link between Biofilm Formation and the Ability of Pathogenic Salmonella Strains to Colonize Multiple Host Species. Vol. 4. 2017. 1-19 p.
 92. (WHO) WHO. Typhoid [Internet]. Vol. 2017. WHO; 2015. Available from: <http://www.who.int/immunization/diseases/typhoid/en/>
 93. Tumbelaka. Tata Laksana Demam Tifoid Pada Anak. Pediatrics Update. Naskah lengkap Pendidikan Kedokteran Berkelanjutan. Ilmu Kesehat Anak IDAI Jaya. 2003;
 94. Mimi Marleni, Yulia Iriani, Wisman Tjuandra, Theodorus. Ketepatan Uji Tubex TF® dalam Mendiagnosis Demam Tifoid Anakpada Demam Hari ke-4. *J Kedokt DAN Kesehat*. 2012;1:7–11.
 95. Tam FCH, Wang M, Dong B, Leung DTM, Ma CH, Lim PL. New rapid test for paratyphoid a fever: usefulness, cross-detection, and solution. *Diagn Microbiol Infect Dis* [Internet]. 2008;62(2):142–50. Available from: <http://www.sciencedirect.com/science/article/pii/S073288930800309X>
 96. J Olsen S, Pruckler J, Bibb W, My Thanh Nguyen T, Trinh Tran M, Minh Nguyen T, et al. Evaluation of Rapid Diagnostic Test for Typhoid Fever. Vol. 42. 2004. 1885-1889 p.
 97. Ruiz N, Kahne D, Silhavy TJ. Advances in understanding bacterial outer-membrane biogenesis. *Nat Rev Microbiol* [Internet]. 2006;4:57. Available

- from: <http://dx.doi.org/10.1038/nrmicro1322>
98. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *N Engl J Med*. 2002/11/29 ed. 2002;347(22):1770–82.
 99. Nasronudin. *Immunopatogenesis molekuler, Diagnosis dan Penatalaksanaan Demam Tifoid Masa Kini. Penyakit Infeksi di Indonesia Solusi Kini & Mendatang*. 2007;
 100. Pastoor R, Hatta M, Abdoel TH, Smits HL. Simple, rapid, and affordable point-of-care test for the serodiagnosis of typhoid fever. *Diagn Microbiol Infect Dis*. 2008/02/16 ed. 2008;61(2):129–34.
 101. Sudoyo AW. *Buku Ajar Ilmu Penyakit Dalam*. Indonesia: Jakarta: Interna Publishing ; 2009.
 102. Tanto C, Liwang F, Hanifati S, Pradipta EA. *Kapita Selekta Kedokteran Jilid II*. In Jakarta: Media Aesculapius; 2016. p. 721–3.
 103. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL. *Harrison's Principles of Internal Medicine*. In Singapore: McGraw-Hill Inc.; 2013.
 104. Prof. dr. Syarifuddin Wahid Sp.PA (K), Sp.F P., dr. Upik A. Miskad Sp.PA (K) P., Wijaya A. *IMUNOLOGI Lebih Mudah Dipahami*. Brillian Internasional; 2016.
 105. Abbas AK, Lichtman AH, Pillai S. *Basic Immunology*. Vol. 5th editio. Elsevier; 2016.
 106. HATTA M, SMITS HL. DETECTION OF SALMONELLA TYPHI BY NESTED POLYMERASE CHAIN REACTION IN BLOOD, URINE, AND STOOL SAMPLES. *Am J Trop Med Hyg* [Internet]. 2007;76(1):139–43. Available from: <http://www.ajtmh.org/content/journals/10.4269/ajtmh.2007.76.139>
 107. Luer S, Troller R, Aebi C. Antibacterial and antiinflammatory kinetics of curcumin as a potential antimucositis agent in cancer patients. *Nutr Cancer*. 2012;64(7):975–81.
 108. Stokes NR, Sievers J, Barker S, Bennett JM, Brown DR, Collins I, et al. Novel inhibitors of bacterial cytokinesis identified by a cell-based antibiotic screening assay. *J Biol Chem*. 2005 Dec;280(48):39709–15.
 109. Hjorth Tønnesen H, de Vries HJ, Karlsen J, Beijersbergen Van Henegouwen G. *Studies on curcumin and curcuminoids IX: Investigation of the photobiological*

- activity of curcumin using bacterial indicator systems. *J Pharm Sci.* 1987 May 1;76:371–3.
110. Yesil S, Tanyildiz HG, Tekgunduz SA, Toprak S, Fettah A, Dikmen AU, et al. Vitamin D receptor polymorphisms in immune thrombocytopenic purpura. *Pediatr Int* [Internet]. 2017 Jun 1;59(6):682–5. Available from: <https://doi.org/10.1111/ped.13273>
 111. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. *Cell Mol Biol (Noisy-le-grand)* [Internet]. 2003;49(2):277–300. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/12887108>
 112. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. *Am J Physiol Renal Physiol.* 2005 Jul;289(1):F8–28.
 113. Dini C, Bianchi A. The potential role of vitamin D for prevention and treatment of tuberculosis and infectious diseases. *Ann Ist Super Sanita.* 2012;48(3):319–27.
 114. Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. *Nat Biotechnol.* 2006 Dec;24(12):1551–7.
 115. Jenssen H, Hamill P, Hancock REW. Peptide antimicrobial agents. *Clin Microbiol Rev.* 2006 Jul;19(3):491–511.
 116. Liu PT, Krutzik SR, Modlin RL. Therapeutic implications of the TLR and VDR partnership. *Trends Mol Med.* 2007 Mar;13(3):117–24.
 117. Wehkamp J, Schaubert J, Stange EF. Defensins and cathelicidins in gastrointestinal infections. *Curr Opin Gastroenterol.* 2007 Jan;23(1):32–8.
 118. Proud D, Sanders SP, Wiehler S. Human rhinovirus infection induces airway epithelial cell production of human beta-defensin 2 both in vitro and in vivo. *J Immunol.* 2004 Apr;172(7):4637–45.
 119. Bergman P, Walter-Jallow L, Broliden K, Agerberth B, Soderlund J. The antimicrobial peptide LL-37 inhibits HIV-1 replication. *Curr HIV Res.* 2007 Jul;5(4):410–5.

LAMPIRAN : SURAT PERSETUJUAN ETIKA PENELITIAN



**KEMENTERIAN RISET, TEKNOLOGI DAN PENDIDIKAN TINGGI
UNIVERSITAS HASANUDDIN
FAKULTAS KEDOKTERAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
KOMITE ETIK PENELITIAN KESEHATAN**



Sekretariat : Lantai 3 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081225704670 e-mail : agussalimbukhari@yahoo.com

REKOMENDASI PERSETUJUAN ETIK

Nomor : 901 / H4.8.4.5.31 / PP36-KOMETIK / 2018

Tanggal: 31 Oktober 2018

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH18090580		No Sponsor	
Peneliti Utama	dr. Ami Febriza Achmad, M.Kes		Protokol	
Judul Peneliti	Efek Curcumin Terhadap Ekspresi Gen mRNA Cathelicidin Antimicrobial Peptide (CAMP) DAN Kadar Vitamin D Reseptor (VDR) pada Mencit Yang Telah Diinduksi Dengan Salmonella Thypi			
No Versi Protokol	2		Tanggal Versi	16 Oktober 2018
No Versi PSP			Tanggal Versi	
Tempat Penelitian	Laboratorium Biologi Molekuler dan Imunologi Fakultas Kedokteran Universitas Hasanuddin Makassar			
Jenis Review	<input type="checkbox"/> Exempted	<input checked="" type="checkbox"/> Expedited	Masa Berlaku	Frekuensi review lanjutan
	<input type="checkbox"/> Fullboard	Tanggal	31 Oktober 2018 sampai 31 Oktober 2019	
Ketua Komisi Etik Penelitian	Nama	Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian	Nama	dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN HASIL PEMERIKSAAN LABORATORIUM



MACROGEN
Advancing through Genomics

Mochammad Hatta
BTN ANTARA B6/6,
Perintis Kemerdekaan, Km.9
90245

MH030119-001

Order date : 2019/01/03
Packing date : 2019/01/07

Page : 2 / 1/2

Oligo	CAMP_Forward							
SEQ	GCCGCTGATTCTTTGACAT							
GC%	MW		Yield		scale (umoles)	Tm [⊙]		
	calculated	measured	OD	nmol				
45.9	8.003,2	8.000,1	5,7	20,5	0,2	66,3		
vol. for 100pmol/ul		Purification		Modification				
705		MOPC						
Oligo	CAMP_Reverse							
SEQ	GCCAAGGCAGGCCTACTACT							
GC%	MW		Yield		scale (umoles)	Tm [⊙]		
	calculated	measured	OD	nmol				
45.8	8.003,4	8.003,4	6,3	20,4	0,2	56,7		
vol. for 100pmol/ul		Purification		Modification				
705		MOPC						
Oligo	GAPDH_Forward							
SEQ	GACCACAGTCCATGCCATCA							
GC%	MW		Yield		scale (umoles)	Tm [⊙]		
	calculated	measured	OD	nmol				
49.2	8.011,2	8.005,9	6,8	23,5	0,2	64,7		
vol. for 100pmol/ul		Purification		Modification				
708		MOPC						
Oligo	GAPDH_Reverse							
SEQ	CATCACGCCACAGTTTCC							
GC%	MW		Yield		scale (umoles)	Tm [⊙]		
	calculated	measured	OD	nmol				
51.4	8.011,7	8.023,5	6,4	21,2	0,2	64,9		
vol. for 100pmol/ul		Purification		Modification				
711		MOPC						

Username: 1st bioMerieux service engineer

Measurement parameters

Reader: 270

Instrument serial number: 1211006960

Measurement mode: Absorbance

Measurement wavelength: 450 nm

Read mode: Normal

Unit: OD

Date: 03/16/19, Time: 4:37:12 PM

Raw data

	1	2	3	4	5	6	7	8	9	10	11	12
A	2.212	1.878	0.175	0.231	0.202	0.112	0.147	0.199	0.223	0.155	0.131	0.195
B	1.288	1.556	0.226	0.132	0.242	0.18	0.209	0.181	0.19	0.146	0.177	0.127
C	0.908	0.734	0.246	0.172	0.156	0.228	0.245	0.209	0.223	0.255	0.246	0.218
D	0.482	0.354	0.218	0.182	0.251	0.195	0.192	0.238	0.222	0.172	0.225	0.187
E	0.224	0.31	0.24	0.194	0.222	0.174	0.268	0.202	0.275	0.215	0.279	0.223
F	0.119	0.185	0.23	0.256	0.282	0.24	0.283	0.261	0.213	0.237	0.274	0.2
G	0.121	0.089	0.244	0.194	0.223	0.193	0.211	0.283	0.281	0.225	0.276	0.232
H	0.058	0.048	0.26	0.238	0.288	0.284	0.311	0.253	0.278	0.204	0.276	0.228

Username: 1st bioMerieux service engineer

Measurement parameters

Reader: 270
Instrument serial number: 1211006860
Measurement mode: Absorbance
Measurement wavelength: 450 nm
Read mode: Normal
Unit: OD
Date: 03/17/19, Time: 3:29:25 PM

Raw data

	1	2	3	4	5	6	7	8	9	10	11	12
A	1.858	2.186	0.164	0.106	0.123	0.167	0.211	0.155	0.153	0.183	0.178	0.128
B	1.531	1.263	0.132	0.216	0.189	0.129	0.159	0.121	0.194	0.148	0.17	0.128
C	0.921	0.713	0.21	0.146	0.153	0.223	0.232	0.188	0.216	0.19	0.149	0.183
D	0.395	0.409	0.209	0.175	0.156	0.206	0.231	0.205	0.225	0.187	0.206	0.166
E	0.223	0.295	0.313	0.261	0.333	0.301	0.304	0.25	0.321	0.269	0.333	0.285
F	0.172	0.124	0.248	0.314	0.322	0.304	0.266	0.302	0.301	0.243	0.264	0.318
G	0.112	0.084	0.283	0.315	0.345	0.299	0.315	0.251	0.343	0.307	0.348	0.284
H	0.058	0.052	0.297	0.281	0.342	0.314	0.312	0.262	0.327	0.259	0.322	0.29

VDR Plate 3

Username: 1st bioMerieux service engineer

Measurement parameters

Reader: 270
Instrument serial number: 1211005880
Measurement mode: Absorbance
Measurement wavelength: 450 nm
Read mode: Normal
Unit: OD
Date: 03/17/19, Time: 3:41:09 PM

Raw data

	1	2	3	4	5	6	7	8	9	10	11	12
A	2.191	1.875	0.21	0.154	0.186	0.146	0.128	0.184	0.219	0.171	0.194	0.216
B	1.534	1.284	0.227	0.191	0.231	0.167	0.224	0.152	0.197	0.259	0.261	0.215
C	0.706	0.932	0.222	0.172	0.199	0.231	0.213	0.169	0.216	0.25	0.237	0.199
D	0.479	0.333	0.25	0.176	0.24	0.194	0.236	0.208	0.27	0.218	0.282	0.216
E	0.22	0.306	0.058	0.06	0.062	0.061	0.058	0.058	0.056	0.057	0.062	0.058
F	0.187	0.119	0.061	0.058	0.058	0.057	0.061	0.062	0.058	0.062	0.06	0.056
G	0.115	0.087	0.057	0.058	0.057	0.058	0.059	0.058	0.061	0.059	0.058	0.062
H	0.062	0.056	0.059	0.061	0.061	0.06	0.057	0.059	0.059	0.061	0.057	0.057

Name : dr. Ami Febriza Achmad
 Date : 16-3-2019
 Plate : 1
 Assay : Gen CAMP

	1	2	3	4	5	6	7	8	9	10	11	12
A	GAPDH-1 ✓	GAPDH-1 ✓	GAPDH-1 ✓	A01 ✓	A01 ✓	A01 ✓	A02 ✓	A02 ✓	A02 ✓	A03 ✓	A03 ✓	A03 ✓
B	GAPDH-2 ✓	GAPDH-2 ✓	GAPDH-2 ✓	A04 ✓	A04 ✓	A04 ✓	A05 ✓	A05 ✓	A05 ✓	B01 ✓	B01 ✓	B01 ✓
C	GAPDH-3 ✓	GAPDH-3 ✓	GAPDH-3 ✓	B02 ✓	B02 ✓	B02 ✓	B03 ✓	B04 ✓	B05 ✓	B04 ✓	B04 ✓	B04 ✓
D	GAPDH-4 ✓	GAPDH-4 ✓	GAPDH-4 ✓	B05 ✓	B05 ✓	B05 ✓	C01 ✓	C01 ✓	C01 ✓	C02 ✓	C02 ✓	C02 ✓
E	GAPDH-5 ✓	GAPDH-5 ✓	GAPDH-5 ✓	C03 ✓	C04 ✓	C05 ✓	C04 ✓	C04 ✓	C04 ✓	C05 ✓	C05 ✓	C05 ✓
F	GAPDH-6 ✓	GAPDH-6 ✓	GAPDH-6 ✓	D01 ✓	D01 ✓	D01 ✓	D02 ✓	D02 ✓	D02 ✓	D03 ✓	D03 ✓	D03 ✓
G	GAPDH-7 ✓	GAPDH-7 ✓	GAPDH-7 ✓	D04 ✓	D04 ✓	D04 ✓	D05 ✓	D05 ✓	D05 ✓			
H												

Remarks : 40 Cycle ; 94 C - 10 s and 56 C - 30 s

Name : dr. Ani Febriza Achmad

Date : 17-3-2019

Plate : 5

Assay : Gen CAMP

	1	2	3	4	5	6	7	8	9	10	11	12
A	GAPDH-1 ✓	GAPDH-1 ✓	GAPDH-1 ✓	A21 ✓	A21 ✓	A21 ✓	A22 ✓	A22 ✓	A22 ✓	A23 ✓	A23 ✓	A23 ✓
B	GAPDH-2 ✓	GAPDH-2 ✓	GAPDH-2 ✓	A24 ✓	A24 ✓	A24 ✓	A25 ✓	A25 ✓	A25 ✓	B21 ✓	B21 ✓	B21 ✓
C	GAPDH-3 ✓	GAPDH-3 ✓	GAPDH-3 ✓	B22 ✓	B22 ✓	B22 ✓	B23 ✓	B24 ✓	B25 ✓	B24 ✓	B24 ✓	B24 ✓
D	GAPDH-4 ✓	GAPDH-4 ✓	GAPDH-4 ✓	B25 ✓	B25 ✓	B25 ✓	C21 ✓	C21 ✓	C21 ✓	C22 ✓	C22 ✓	C22 ✓
E	GAPDH-5 ✓	GAPDH-5 ✓	GAPDH-5 ✓	C23 ✓	C24 ✓	C25 ✓	C24 ✓	C24 ✓	C24 ✓	C25 ✓	C25 ✓	C25 ✓
F	GAPDH-6 ✓	GAPDH-6 ✓	GAPDH-6 ✓	D21 ✓	D21 ✓	D21 ✓	D22 ✓	D22 ✓	D22 ✓	D23 ✓	D23 ✓	D23 ✓
G	GAPDH-7 ✓	GAPDH-7 ✓	GAPDH-7 ✓	D24 ✓	D24 ✓	D24 ✓	D25 ✓	D25 ✓	D25 ✓			
H												

Remarks : 40 Cycle ; 94 C - 10 s and 56 C - 30 s

Name : dr. Amri Febriza Achmad

Date : 17-3-2019

Plate : 4

Assay : Gen CAMP

	1	2	3	4	5	6	7	8	9	10	11	12
A	GAPDH-1 ✓	GAPDH-1 ✓	GAPDH-1 ✓	A16 ✓	A16 ✓	A16 ✓	A17 ✓	A17 ✓	A17 ✓	A18 ✓	A18 ✓	A18 ✓
B	GAPDH-2 ✓	GAPDH-2 ✓	GAPDH-2 ✓	A19 ✓	A19 ✓	A19 ✓	A20 ✓	A20 ✓	A20 ✓	B16 ✓	B16 ✓	B16 ✓
C	GAPDH-3 ✓	GAPDH-3 ✓	GAPDH-3 ✓	B17 ✓	B17 ✓	B17 ✓	B18 ✓	B18 ✓	B18 ✓	B19 ✓	B19 ✓	B19 ✓
D	GAPDH-4 ✓	GAPDH-4 ✓	GAPDH-4 ✓	B20 ✓	B20 ✓	B20 ✓	C16 ✓	C16 ✓	C16 ✓	C17 ✓	C17 ✓	C17 ✓
E	GAPDH-5 ✓	GAPDH-5 ✓	GAPDH-5 ✓	C18 ✓	C19 ✓	C11 ✓	C19 ✓	C19 ✓	C19 ✓	C20 ✓	C20 ✓	C20 ✓
F	GAPDH-6 ✓	GAPDH-6 ✓	GAPDH-6 ✓	D16 ✓	D16 ✓	D16 ✓	D17 ✓	D17 ✓	D17 ✓	D18 ✓	D18 ✓	D18 ✓
G	GAPDH-7 ✓	GAPDH-7 ✓	GAPDH-7 ✓	D19 ✓	D19 ✓	D19 ✓	D20 ✓	D20 ✓	D20 ✓			
H												

Remarks : 40 Cycle ; 94 C - 10 s and 56 C - 30 s

Name : dr. Anil Febriza Achmad

Date : 17-3-2019

Plate : 3

Assay : Geni CAMP

	1	2	3	4	5	6	7	8	9	10	11	12
A	GAPDH-1 ✓	GAPDH-1 ✓	GAPDH-1 ✓	A11 ✓	A11 ✓	A11 ✓	A12 ✓	A12 ✓	A12 ✓	A13 ✓	A13 ✓	A13 ✓
B	GAPDH-2 ✓	GAPDH-2 ✓	GAPDH-2 ✓	A14 ✓	A14 ✓	A14 ✓	A15 ✓	A15 ✓	A15 ✓	B11 ✓	B11 ✓	B11 ✓
C	GAPDH-3 ✓	GAPDH-3 ✓	GAPDH-3 ✓	B12 ✓	B12 ✓	B12 ✓	B13 ✓	B14 ✓	B15 ✓	B14 ✓	B14 ✓	B14 ✓
D	GAPDH-4 ✓	GAPDH-4 ✓	GAPDH-4 ✓	B15 ✓	B15 ✓	B15 ✓	C11 ✓	C11 ✓	C11 ✓	C12 ✓	C12 ✓	C12 ✓
E	GAPDH-5 ✓	GAPDH-5 ✓	GAPDH-5 ✓	C13 ✓	C14 ✓	C15 ✓	C14 ✓	C14 ✓	C14 ✓	C15 ✓	C15 ✓	C15 ✓
F	GAPDH-6 ✓	GAPDH-6 ✓	GAPDH-6 ✓	D11 ✓	D11 ✓	D11 ✓	D12 ✓	D12 ✓	D12 ✓	D13 ✓	D13 ✓	D13 ✓
G	GAPDH-7 ✓	GAPDH-7 ✓	GAPDH-7 ✓	D14 ✓	D14 ✓	D14 ✓	D15 ✓	D15 ✓	D15 ✓			
H												

Remarks : 40 Cycle : 94 C - 10 s and 56 C - 30 s

Name : dr. Anil Febrita Achmad

Date : 16-3-2019

Plate : 2

Assay : Gen CAMP

	1	2	3	4	5	6	7	8	9	10	11	12
A	GAPDH-1 ✓	GAPDH-1 ✓	GAPDH-1 ✓	A06 ✓	A06 ✓	A06 ✓	A07 ✓	A07 ✓	A07 ✓	A08 ✓	A08 ✓	A08 ✓
B	GAPDH-2 ✓	GAPDH-2 ✓	GAPDH-2 ✓	A09 ✓	A09 ✓	A09 ✓	A10 ✓	A10 ✓	A10 ✓	B06 ✓	B06 ✓	B06 ✓
C	GAPDH-3 ✓	GAPDH-3 ✓	GAPDH-3 ✓	B07 ✓	B07 ✓	B07 ✓	B08 ✓	B09 ✓	B10 ✓	B09 ✓	B09 ✓	B09 ✓
D	GAPDH-4 ✓	GAPDH-4 ✓	GAPDH-4 ✓	B10 ✓	B10 ✓	B10 ✓	C06 ✓	C06 ✓	C06 ✓	C07 ✓	C07 ✓	C07 ✓
E	GAPDH-5 ✓	GAPDH-5 ✓	GAPDH-5 ✓	C08 ✓	C09 ✓	C10 ✓	C09 ✓	C09 ✓	C09 ✓	C10 ✓	C10 ✓	C10 ✓
F	GAPDH-6 ✓	GAPDH-6 ✓	GAPDH-6 ✓	D06 ✓	D06 ✓	D06 ✓	D07 ✓	D07 ✓	D07 ✓	D08 ✓	D08 ✓	D08 ✓
G	GAPDH-7 ✓	GAPDH-7 ✓	GAPDH-7 ✓	D09 ✓	D09 ✓	D09 ✓	D10 ✓	D10 ✓	D10 ✓			
H												

Remarks : 40 Cycle ; 94 C - 10 s and 56 C - 30 s

do Ami
List Berat Badan dan Dosis Pengobatan

NO	KIP	Kode Mersit	BB Awal	Berat Badan dan Dosis Pengobatan												BB 2 minggu setelah pengobatan	
				Hari 1		Hari 2		Hari 3		Hari 4		Hari 5		Hari 6			
				BB	Dosis	BB	Dosis	BB	Dosis	BB	Dosis	BB	Dosis		BB		
1	Ag BB Mersit	Kepala	35.0	30.1	6.0	31.2	6.3	32.3	6.3	33.5	6.3	33.0	6.4	33.0	31.2		
2		Punggung	33.1	32.5	6.5	33.0	6.6	34.2	6.8	35.1	7.0	35.0	7.1	36.3	37.6		
3		Ekor	31.7	30.8	6.2	31.2	6.2	32.7	6.5	33.5	6.1	33.1	6.0	33.2	34.8		
4		K. Depan KA	40.8	38.9	7.8	40.5	8.1	41.8	8.4	42.4	8.5	42.4	8.3	44.5	44.8		
5		K. Depan KI	34.1	33.8	6.8	34.2	6.8	35.4	6.7	35.7	6.5	35.0	6.7	36.1	36.6		
6	K. Belakang	35.2	33.0	6.6	33.5	6.7	35.2	6.8	35.5	6.7	35.8	6.8	35.8	36.5			
7	Ag BB Mersit	Kepala	33.0	32.5	25.8	31.7	32.5	34.5	33.7	34.7	33.8	34.8	33.8	35.1	35.1		
8		Punggung	34.1	31.2	17.4	32.8	15.8	32.3	32.8	32.8	33.0	32.8	32.3	33.3	33.3		
9		Ekor	35.4	34.0	13.4	35.1	12.5	32.3	32.8	33.0	33.2	33.1	33.3	34.1	34.1		
10		K. Depan KA	31.3	30.2	12.0	31.4	13.6	31.3	32.6	32.6	32.6	32.6	32.6	33.5	34.2		
11		K. Depan KI	34.2	32.8	18.1	33.7	12.5	33.6	33.4	33.9	33.8	34.2	33.7	34.2	34.2		
12	K. Belakang	30.0	28.7	13.3	30.1	12.8	30.7	32.3	33.1	33.0	33.0	33.2	34.3	34.3			
13	Ag BB Mersit	Kepala	30.4	30.0	6.0	30.2	6.0	30.4	29.8	30.0	30.4	6.1	30.8	31.8	6.3	30.5	30.0
14		Punggung	31.1	30.1	9.0	30.7	9.9	31.1	31.8	31.7	32.7	4.0	33.0	33.0	6.8	32.8	32.1
15		Ekor	31.6	30.2	6.0	30.82	31.2	6.3	30.4	31.2	31.8	6.4	30.8	31.6	6.0	31.7	31.1
16		K. Depan KA	33.4	32.1	9.4	33.07	33.7	6.7	33.8	34.0	34.0	34.2	34.2	34.5	34.8	34.5	
17		K. Depan KI	31.7	29.5	9.8	31.18	31.0	6.8	30.2	30.4	30.5	31.1	31.7	31.7	31.8	30.4	30.8
18	K. Belakang	25.8	25.0	9.8	25.8	31.1	6.0	32.5	30.0	31.8	31.8	32.0	33.3	33.3	33.3	34.5	

NO	KIP	Kode Mersit	BB Awal	Berat Badan dan Dosis Pengobatan												BB 2 minggu setelah pengobatan
				Hari 1		Hari 2		Hari 3		Hari 4		Hari 5		Hari 6		
				BB	Dosis	BB	Dosis	BB	Dosis	BB	Dosis	BB	Dosis		BB	
19	Ag BB Mersit	Kepala	38.0	35.4	3.5	36.0	3.5	37.5	3.7	37.3	3.7	36.4	3.6	37.1	37.0	
20		Punggung	36.5	35.0	1.4	37.0	3.6	37.4	3.7	38.2	3.7	38.0	3.7	38.8	38.8	
21		Ekor	32.8	30.1	2.9	33.4	3.3	34.2	3.8	34.5	3.4	34.2	3.4	34.2	35.2	
22		K. Depan KA	40.5	37.2	3.6	40.8	4.0	41.0	4.0	42.4	4.2	42.2	4.1	44.1	43.2	
23		K. Depan KI	32.3	30.3	1.0	33.5	3.3	34.0	3.3	34.1	3.3	34.3	3.4	35.8	35.0	
24	K. Belakang	30.5	28.0	2.7	30.2	2.8	30.4	4.0	30.8	3.9	30.9	3.9	30.7	30.7		
25	Ag BB Mersit	Kepala	33.5	27.1		25.1		23.8		24.9		25.4		26.8	23.8	
26		Punggung	38.7	36.8		33.8		33.3		35.2		36.0		37.1	36.1	
27		Ekor	34.8	30.1		31.0		32.4		32.7		33.1		34.0	34.6	
28		K. Depan KA	33.5	32.5		32.0		31.8		31.8		32.0		32.8	34.1	
29		K. Depan KI	36.8	34.8		34.0		34.6		35.1		36.0		36.3	36.3	
30	K. Belakang	40.6	38.2		37.6		30.7		27.5		27.9		28.3	29.6		

LAMPIRAN FOTO PENELITIAN





